IL148300A0 - Mammalian cytokines; related reagents and methods - Google Patents

Mammalian cytokines; related reagents and methods

Info

Publication number
IL148300A0
IL148300A0 IL14830000A IL14830000A IL148300A0 IL 148300 A0 IL148300 A0 IL 148300A0 IL 14830000 A IL14830000 A IL 14830000A IL 14830000 A IL14830000 A IL 14830000A IL 148300 A0 IL148300 A0 IL 148300A0
Authority
IL
Israel
Prior art keywords
methods
related reagents
mammalian cytokines
cytokines
mammalian
Prior art date
Application number
IL14830000A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26860707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148300(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL148300A0 publication Critical patent/IL148300A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
IL14830000A 1999-09-09 2000-09-08 Mammalian cytokines; related reagents and methods IL148300A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US16461699P 1999-11-10 1999-11-10
PCT/US2000/024686 WO2001018051A2 (en) 1999-09-09 2000-09-08 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IL148300A0 true IL148300A0 (en) 2002-09-12

Family

ID=26860707

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14830000A IL148300A0 (en) 1999-09-09 2000-09-08 Mammalian cytokines; related reagents and methods

Country Status (15)

Country Link
EP (1) EP1210434B2 (ko)
JP (6) JP4505166B2 (ko)
KR (1) KR100894359B1 (ko)
CN (1) CN100529076C (ko)
AR (1) AR035560A1 (ko)
AT (1) ATE389019T1 (ko)
AU (2) AU780163B2 (ko)
CA (1) CA2388562C (ko)
DE (1) DE60038304T3 (ko)
ES (1) ES2300276T5 (ko)
HK (1) HK1044170B (ko)
HU (1) HU230679B1 (ko)
IL (1) IL148300A0 (ko)
MX (1) MXPA02002684A (ko)
WO (1) WO2001018051A2 (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
NZ522146A (en) 2000-05-10 2004-10-29 Schering Corp Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
CA2506672C (en) 2002-12-23 2012-04-17 Schering Corporation Il-23 for treating cutaneous wounds
PL1601694T3 (pl) * 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
CA2525184C (en) 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
WO2007024846A2 (en) * 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
ATE555125T1 (de) * 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CN101675076B (zh) 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2305304A4 (en) * 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULATOR WITH EP1 AGONIST
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP3456740A1 (en) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
US10106592B2 (en) * 2013-09-24 2018-10-23 Medicenna Therapeutics Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
SG11201701423RA (en) 2014-09-03 2017-03-30 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0790255T3 (da) * 1989-12-22 2007-11-26 Hoffmann La Roche Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
CO4810232A1 (es) * 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
WO1999040195A1 (en) * 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods

Also Published As

Publication number Publication date
KR20020034185A (ko) 2002-05-08
AR035560A1 (es) 2004-06-16
EP1210434A2 (en) 2002-06-05
DE60038304T3 (de) 2017-04-06
WO2001018051A3 (en) 2001-09-20
JP2015051005A (ja) 2015-03-19
HUP0301102A3 (en) 2005-11-28
JP2003510038A (ja) 2003-03-18
MXPA02002684A (es) 2002-07-30
ES2300276T5 (es) 2017-06-02
ATE389019T1 (de) 2008-03-15
JP4505166B2 (ja) 2010-07-21
CN1387571A (zh) 2002-12-25
JP2010233571A (ja) 2010-10-21
DE60038304D1 (de) 2008-04-24
EP1210434B2 (en) 2016-12-14
AU2008240348B2 (en) 2012-07-12
JP2009268467A (ja) 2009-11-19
ES2300276T3 (es) 2008-06-16
JP2013128489A (ja) 2013-07-04
KR100894359B1 (ko) 2009-04-22
AU7360800A (en) 2001-04-10
CN100529076C (zh) 2009-08-19
HK1044170A1 (en) 2002-10-11
AU780163B2 (en) 2005-03-03
JP2007045830A (ja) 2007-02-22
CA2388562A1 (en) 2001-03-15
DE60038304T2 (de) 2009-03-19
HU230679B1 (en) 2017-08-28
EP1210434B1 (en) 2008-03-12
JP6140122B2 (ja) 2017-05-31
JP4969610B2 (ja) 2012-07-04
HK1044170B (zh) 2008-08-01
CA2388562C (en) 2014-07-22
AU2008240348A1 (en) 2008-11-27
HUP0301102A2 (hu) 2003-07-28
WO2001018051A2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
IL148300A0 (en) Mammalian cytokines; related reagents and methods
AU7103198A (en) Mammalian cytokines; related reagents and methods
HUP0004019A3 (en) Mammalian cytokine: interleukin-b30 and related reagents
HK1043831A1 (zh) 光學測試儀器及其方法
IL158368A0 (en) Methods and reagents for cell transplantation
AU6700598A (en) Intron-mediated recombinant techniques and reagents
AU2001274920A1 (en) Mammalian receptor proteins; related reagents and methods
GB9927332D0 (en) Novel antibody and uses thereof
AU3873200A (en) Mammalian cytokines; related reagents and methods
AU8173098A (en) Neuroprotective methods and reagents
AU2661199A (en) Mammalian receptor proteins; related reagents and methods
AU1919201A (en) Mammalian receptor proteins; related reagents and methods
AU2001233212A1 (en) Mammalian cytokines; receptors; related reagents and methods
GB0111218D0 (en) Assays methods and means
GB9907687D0 (en) Assays methods and means
AU4586700A (en) Improved assay and reagents therefor
EP1239039A4 (en) NEW POLYPEPTIDE AND ENCODING DNA
HUP0201660A2 (en) Novel polypeptide and dna thereof
AU1604701A (en) Mammalian genes; related reagents and methods
EP1241256A4 (en) NEW GENE AND USE
GB9807848D0 (en) Assay method and means
GB9704162D0 (en) Assay methods and means
GB2348701B (en) Assays,methods and means
GB9813778D0 (en) Assay methods and means
ZA989343B (en) Mammalian cytokines; related reagents.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed